Strategies to Mitigate Impacts of the COVID-19 Pandemic on Patients Treated with Deep Brain Stimulation
In the wake of the COVID-19 crisis, 160,000 patients worldwide who have undergone deep brain stimulation (DBS) are now experiencing critical treatment disruptions. These include patients treated for Parkinson ’s disease, dystonia, epilepsy and essential tremor as well as for psychiatric disorders, like treatment-resistant obsessive compulsive disorder and Tourette syndrome. With many hospitals overburdened1 and the potential for community-based infection still high (and increasing), shifting to various forms of telemedicine DBS care has become part of a necessary “natural experiment” to mitigate risk for infection and continue care throughout the pandemic.
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - Category: Neurology Authors: Kristin Kostick, Eric A. Storch, Peter Zuk, Jennifer-Blumenthal-Barby, Laura Torgerson, Daniel Yoshor, Sameer Sheth, Ashwin Viswanathan, Arjun Tarakad, Joohi Jimenez-Shahed, Wayne Goodman, Gabriel L ázaro-Muñoz Source Type: research
More News: Brain | COVID-19 | Deep Brain Stimulation | Dystonia | Epilepsy | Hospitals | Neurology | Obsessive Compulsive Disorder | Pandemics | Parkinson's Disease | Psychiatry | Tourette Syndrome